Program Description
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by numerous systemic symptoms and may progress to leukemia. The only cure for MF is allogeneic hematopoietic stem cell transplantation (ASCT), for which many patients are not eligible. These patients may require first-line therapy JAK inhibitors, but time-limited efficacy and potentially serious adverse effects often lead to intolerance or resistance. Continued clinical investigations have spurred a greater understanding of potential new therapies with the aim of modifying MF disease progression. Oncology pharmacists are well positioned to bridge patients and the multidisciplinary care team to individualize treatment regimens and promote patient-centered care. In this program, oncology experts will come together to discuss the importance of multidisciplinary care teams and their crucial role in monitoring adherence and managing treatment-related adverse effects to improve outcomes for patients with MF.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: August 30, 2023
Expiration date: October 30, 2023
Time to complete activity: 1.5 hours
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Individualize treatment for patients with myelofibrosis (MF) through knowledge of clinical guidelines and characteristics of disease
- Explain emerging treatment strategies and clinical evidence in treating MF
- Distinguish the role of the pharmacist on the multidisciplinary care team in optimizing treatment outcomes and quality of life in patients with MF
Amber B. Clemmons, PharmD, BCOP, FHOPA
Clinical Professor
University of Georgia (UGA) College of Pharmacy
Clinical Pharmacy Specialist - Hematology/BMT
Augusta University (AU) Medical Center
PGY2 Oncology Residency Director
UGA / AU Medical Center
Augusta, Georgia
Firas El Chaer, MD
Assistant Professor of Medicine
Medical Director of Chronic & Acute Leukemia, MDS & MPN Clinical Research Team
Infusion Center Medical Director
Division of Hematology/Oncology
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Amelia Hodson, MSN, APRN, AGACNP-BC
Nurse Practitioner, Hematology/Oncology
Emily Couric Clinical Cancer Center
University of Virginia Health
Charlottesville, Virginia
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-304-L01-P. The activity is available for CE credit through October 30, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Firas El Chaer, MD, has the following relevant financial relationships with commercial interests to disclose:
- Grant/Research Support: Amgen, Celgene, Sumitomo Dainippon Pharma Oncology, Sanofi, Bristol Myers Squibb, FibroGen.
- Consultant: SDP Oncology, Amgen.
- Non-Financial Consultancy Support: DAVA Oncology, Amgen, Association of Community Cancer Centers.
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Amber B. Clemmons, PharmD, BCOP, FHOPA
Amelia Hodson, MSN
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms